KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Capital Expenditures (2016 - 2022)

Historic Capital Expenditures for TherapeuticsMD (TXMD) over the last 12 years, with Q2 2022 value amounting to -$21000.0.

  • TherapeuticsMD's Capital Expenditures fell 15121.95% to -$21000.0 in Q2 2022 from the same period last year, while for Sep 2022 it was $21000.0, marking a year-over-year decrease of 8960.4%. This contributed to the annual value of $34000.0 for FY2021, which is 8357.49% down from last year.
  • As of Q2 2022, TherapeuticsMD's Capital Expenditures stood at -$21000.0, which was down 15121.95% from $42000.0 recorded in Q1 2022.
  • In the past 5 years, TherapeuticsMD's Capital Expenditures registered a high of $996909.0 during Q3 2019, and its lowest value of -$70000.0 during Q3 2021.
  • Over the past 5 years, TherapeuticsMD's median Capital Expenditures value was $41000.0 (recorded in 2021), while the average stood at $172296.5.
  • In the last 5 years, TherapeuticsMD's Capital Expenditures surged by 474524.42% in 2019 and then crashed by 63846.15% in 2021.
  • Over the past 5 years, TherapeuticsMD's Capital Expenditures (Quarter) stood at $150745.0 in 2018, then surged by 139.2% to $360587.0 in 2019, then crashed by 53.41% to $168000.0 in 2020, then tumbled by 141.67% to -$70000.0 in 2021, then surged by 70.0% to -$21000.0 in 2022.
  • Its Capital Expenditures was -$21000.0 in Q2 2022, compared to $42000.0 in Q1 2022 and -$70000.0 in Q3 2021.